May 11, 2023 7:00 am EDT Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
Apr 10, 2023 7:30 am EDT Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Mar 29, 2023 7:30 am EDT Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 16, 2023 7:30 am EDT Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
Nov 3, 2022 7:30 am EDT Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
